避孕方式与抗苗勒管激素水平:27125例横断面研究
该研究纳入27125名20至46岁美国女性,横断面比较不同避孕方式与抗苗勒管激素(AMH)水平的关系。控制年龄、体重指数等协变量后,复方口服避孕药、阴道环、皮下埋植、孕激素-only片及激素宫内节育器使用者的AMH均值显著低于未避孕者,铜宫内节育器则无显著差异。
要点
- 复方口服避孕药、阴道环、皮下埋植、孕激素-only片及激素宫内节育器使用者AMH均值显著低于未避孕者。
- 铜宫内节育器使用者与未避孕者AMH水平无显著差异。
- 避孕方式与AMH的关联不受自报多囊卵巢综合征诊断影响。
核心结论
- 当前使用激素类避孕与较低的平均AMH水平相关,不同避孕方式的降幅存在差异。
研究设计与样本
- 横断面研究,纳入27125名20至46岁美国女性,通过干血斑卡(95.9%)或静脉穿刺(4.1%)采集AMH。
主要发现
- 复方口服避孕药使用者AMH均值低23.68%(系数0.76,95%CI 0.72-0.81,P<.001)。
- 阴道环使用者低22.07%(系数0.78,95%CI 0.71-0.86,P<.001)。
- 皮下埋植使用者低23.44%(系数0.77,95%CI 0.69-0.85,P<.001)。
- 孕激素-only片使用者低14.80%(系数0.85,95%CI 0.76-0.96,P=.007)。
- 激素宫内节育器使用者低6.73%(系数0.93,95%CI 0.88-0.99,P=.014);铜宫内节育器低1.57%(系数0.98,95%CI 0.92-1.05,P=.600),无显著差异。
临床怎么用
- 解读使用激素避孕女性的AMH时,需考虑所用避孕方式对AMH的降低效应,避免误判卵巢储备。
- 铜宫内节育器使用者AMH水平与未避孕者无显著差异,可按常规解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-Müllerian hormone has become the clinical biomarker-based standard to assess ovarian reserve. As anti-Müllerian hormone testing becomes more common, more individuals are seeking to interpret the values obtained while using contraceptives. To appropriately counsel women, a better understanding of anti-Müllerian hormone levels in women using different contraceptives is needed. OBJECTIVE: To study the association between different forms of contraceptives and anti-Müllerian levels in women of reproductive age. STUDY DESIGN: This is a cross-sectional study including 27,125 US-based women aged 20 to 46 years, accessing reproductive hormone results through Modern Fertility and who provided informed consent to participate in the research. Anti-Müllerian hormone levels were collected through dried blood spot card (95.9%) or venipuncture (4.1%), and previous work has shown high correlation between hormone levels collected by these 2 methods. Multiple linear regressions were run to compare anti-Müllerian hormone levels in women using contraceptives with women not on any contraceptive, controlling for age, age of menarche, body mass index, smoking, sample collection method, cycle day, and self-reported polycystic ovary syndrome diagnosis. We also analyzed whether duration of contraceptive use predicted anti-Müllerian hormone levels in users of the hormonal intrauterine device and combined oral contraceptive pill, given the size of these contraceptive groups. RESULTS: Mean anti-Müllerian hormone levels were statistically significantly lower in women using the combined oral contraceptive pill (23.68% lower; coefficient, 0.76; 95% confidence interval, 0.72-0.81; P<.001), vaginal ring (22.07% lower; coefficient, 0.78; 95% confidence interval, 0.71-0.86; P<.001), hormonal intrauterine device (6.73% lower; coefficient, 0.93; 95% confidence interval, 0.88-0.99; P=.014), implant (23.44% lower; coefficient, 0.77; 95% confidence interval, 0.69-0.85; P<.001), or progestin-only pill (14.80% lower; coefficient, 0.85; 95% confidence interval, 0.76-0.96; P=.007) than women not on any contraceptive when controlling for covariates. Anti-Müllerian hormone levels were not significantly different when comparing women not using any contraceptives to those using the copper intrauterine device (1.57% lower; coefficient, 0.98; 95% confidence interval, 0.92-1.05, P=.600). Associations between contraceptive use and anti-Müllerian hormone levels did not differ based on self-reported polycystic ovary syndrome diagnosis. Duration of hormonal intrauterine device use, but not of combined oral contraceptive pill use, was slightly positively associated with anti-Müllerian hormone levels, although this small magnitude effect is likely not clinically meaningful (coefficient, 1.002; 95% confidence interval, 1.0005-1.003; P=.007). CONCLUSION: Current hormonal contraceptive use is associated with a lower mean anti-Müllerian hormone level than that of women who are not on contraceptives, with variability in the percent difference across contraceptive methods. These data provide guidance for clinicians on how to interpret anti-Müllerian hormone levels assessed while on contraceptives and may facilitate more patients to continue contraceptive use while being evaluated for their ovarian reserve.
引用
- Hariton E, Shirazi TN, Douglas NC, et al. Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. Am J Obstet Gynecol. 2021. PMID: 34126087. doi:10.1016/j.ajog.2021.06.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。